ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Advanced Search Results

  • Title
    ---
  • Authors and Affiliations
    maureen dubreuil
  • 1
  • 2
  • 3
  • 4
  • Next Page »
Search Again »
  • Abstract Number: 1439 • ACR Convergence 2024

    Risk of Hip and Spine Fractures in Axial Spondyloarthritis Is Associated with Treatment Class

    Devin Driscoll1, Navya George2, S. Reza Jafarzadeh3, Christine Peloquin3, Jean Liew3 and Maureen Dubreuil4, 1Boston Medical Center, Boston, MA, 2Boston University Medical Center Internal Medicine Residency Program, Boston, MA, 3Boston University Chobanian & Avedisian School of Medicine, Boston, MA, 4Section of Rheumatology, Boston University School of Medicine, Boston, MA

    Background/Purpose: Individuals with axial spondyloarthritis (axSpA) have a risk of fracture that is nearly double that of the general population, possibly related to chronic inflammation.…
  • Abstract Number: 1480 • ACR Convergence 2024

    Sustained Improvements with Bimekizumab in Spinal Mobility, Physical Function and Health-Related Quality of Life in Patients with Axial Spondyloarthritis: 2-Year Results from Two Phase 3 Studies

    Victoria Navarro Compán1, Maureen Dubreuil2, Karl Gaffney3, Jonathan Kay4, Christine de la Loge5, Ute Massow6, Vanessa Taieb7, Thomas Vaux8 and Atul Deodhar9, 1La Paz University Hospital, Hospital La Paz Institute for Health Research (IdiPAZ), Madrid, Spain, 2Section of Rheumatology, Boston University School of Medicine, Boston, MA, 3Health Care - NHS, Norwich, United Kingdom, 4Division of Rheumatology, Department of Medicine, UMass Chan Medical School and UMass Memorial Medical Center, Worcester, MA, 5UCB Pharma, Brussels, Belgium, 6UCB Pharma, Monheim am Rhein, Germany, 7UCB Pharma, Colombes, France, 8UCB Pharma, Slough, United Kingdom, 9Division of Arthritis and Rheumatic Diseases, Oregon Health & Science University, Portland, OR

    Background/Purpose: In the phase 3 BE MOBILE 1 and 2 studies, bimekizumab (BKZ), a monoclonal IgG1 antibody that inhibits interleukin (IL)-17F in addition to IL-17A,…
  • Abstract Number: 1868 • ACR Convergence 2024

    Opioid Prescription Rates in Patients with Radiographic Axial Spondyloarthritis in the US Between 2008-2021: A Joinpoint Regression Analysis

    Berk Degirmenci1, Christine Peloquin2, Sara Lodi1, Pedro M Machado3, S. Reza Jafarzadeh2, Tuhina Neogi2, Lianne S Gensler4, Maureen Dubreuil5 and Jean Liew2, 1Boston University, Boston, MA, 2Boston University Chobanian & Avedisian School of Medicine, Boston, MA, 3Department of Neuromuscular Diseases and Centre for Rheumatology, University College London, London, United Kingdom, 4Department of Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA, 5Section of Rheumatology, Boston University School of Medicine, Boston, MA

    Background/Purpose: Current axial spondyloarthritis (axSpA) guidelines do not provide recommendations for opioids in pain management. Opioid use is common in axSpA, despite widespread uptake of…
  • Abstract Number: 1891 • ACR Convergence 2024

    Association of Physical Activity Levels on Chronic Opioid Use in Radiographic Axial Spondylitis Patients

    Rutvin Kyada1, Jean Liew2, Maureen Dubreuil3, Matthew Brown4, Mariko Ishimori5, John Reveille6, Michael Ward7, Michael Weisman8 and Lianne S Gensler9, 1Boston University, Boston, MA, 2Boston University Chobanian & Avedisian School of Medicine, Boston, MA, 3Section of Rheumatology, Boston University School of Medicine, Boston, MA, 4King's College London, London, United Kingdom, 5Cedars-Sinai Health System, Los Angeles, CA, 6UTHealth Houston Division of Rheumatology, Houston, 7NIH, Bethesda, MD, 8Stanford University, Los Angeles, CA, 9Department of Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA

    Background/Purpose: Pain remains a common symptom of axial spondyloarthritis (axSpA) despite availability of effective therapies. Physical activity may benefit pain and is guideline recommended but…
  • Abstract Number: 1892 • ACR Convergence 2024

    Early Tumor Necrosis Factor Inhibitor Initiation and Chronic Opioid Use in Individuals with Axial Spondyloarthritis

    Eva Petrow1, Jose Meade Aguilar2, Christine Peloquin3, S. Reza Jafarzadeh3, Tuhina Neogi3, Maureen Dubreuil4 and Jean Liew3, 1Boston University/Boston Medical Center, Boston, MA, 2Boston Medical Center, Boston, MA, 3Boston University Chobanian & Avedisian School of Medicine, Boston, MA, 4Section of Rheumatology, Boston University School of Medicine, Boston, MA

    Background/Purpose: Patients with axial spondyloarthritis (axSpA) bear a substantial burden of chronic opioid use despite the availability of effective treatments like tumor necrosis factor inhibitors…
  • Abstract Number: 0558 • ACR Convergence 2024

    Patient Diagnostic Journey and Time to Diagnosis in Axial Spondyloarthritis: A Retrospective Cohort Study Using US Claims Data

    Maureen Dubreuil1, Marina Magrey2, Kathrin Haeffs3, Evgueni Ivanov4 and Julie Gandrup Horan5, 1Section of Rheumatology, Boston University School of Medicine, Boston, MA, 2Case Western Reserve University School of Medicine/University Hospitals, Richfield, OH, 3UCB Pharma, Monheim, Germany, 4UCB Pharma, Bulle, Switzerland, 5UCB Pharma, Slough, United Kingdom

    Background/Purpose: The journey to axial spondyloarthritis (axSpA) diagnosis is often prolonged and challenging, resulting in poor clinical, psychological, social, and economic outcomes.1 Understanding the factors…
  • Abstract Number: 0592 • ACR Convergence 2024

    Sustained Improvements with Bimekizumab in Patient-Reported Symptoms of Axial Spondyloarthritis: 2-Year Results from Two Phase 3 Studies

    Helena Marzo-Ortega1, Philip Mease2, Maxime Dougados3, Maureen Dubreuil4, Marina Magrey5, Martin Rudwaleit6, Maria Antonietta D'Agostino7, Christine de la Loge8, Ute Massow9, Vanessa Taieb10, Diana Voiniciuc11 and Atul Deodhar12, 1NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust and Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, 2Swedish Medical Center/Providence St. Joseph Health; University of Washington School of Medicine, Seattle, WA, 3Rheumatology Department, Cochin Hospital and Clinical Epidemiology and Biostatistics, University of Paris, INSERM (U1153), Paris, France, 4Section of Rheumatology, Boston University School of Medicine, Boston, MA, 5Case Western Reserve University School of Medicine/University Hospitals, Richfield, OH, 6University of Bielefeld, Klinikum Bielefeld, Bielefeld, Germany, 7Division of Rheumatology, Fondazione Policlinico Universitario Agostino Gemelli IRCSS, Università Cattolica del Sacro Cuore, Rome, Italy, 8UCB Pharma, Brussels, Belgium, 9UCB Pharma, Monheim am Rhein, Germany, 10UCB Pharma, Colombes, France, 11UCB Pharma, Slough, United Kingdom, 12Division of Arthritis and Rheumatic Diseases, Oregon Health & Science University, Portland, OR

    Background/Purpose: In the phase 3 studies, BE MOBILE 1 and 2, bimekizumab (BKZ), a monoclonal IgG1 antibody that selectively inhibits interleukin (IL)-17F in addition to…
  • Abstract Number: 1012 • ACR Convergence 2024

    Disparities in Time to Diagnosis for Radiographic Axial Spondyloarthritis

    Renato Ferrandiz1, Gabriela Rabasa2, Sarah Gasman3, Brooke Mcginley4, Rachael Stovall5, S. Reza Jafarzadeh6, Jean Liew6 and Maureen Dubreuil7, 1North Alabama Medical Center, Florence, AL, 2Department of Developmental Medicine, Boston Children's Hospital, Boston, MA, 3Boston University School of Medicine, Boston, MA, 4Boston University, Boston, MA, 5University of Washington, Seattle, WA, 6Boston University Chobanian & Avedisian School of Medicine, Boston, MA, 7Section of Rheumatology, Boston University School of Medicine, Boston, MA

    Background/Purpose: Radiographic axial spondyloarthritis (r-axSpA; formerly ankylosing spondylitis) has an average diagnostic delay of 7 years, which can lead to a diminished quality of life…
  • Abstract Number: 0437 • ACR Convergence 2023

    Comparative Safety of Biologic and Targeted Synthetic Disease Modifying Anti-Rheumatic Drugs for Cardiovascular Outcomes in Rheumatoid Arthritis

    Xavier Sendaydiego1, Laura Gold2, K Wysham3, Jean liew4, Maureen Dubreuil5, James Andrews1, Pankti Reid6, David Liew7, Radjiv Goulabchand8, Abha Singh9, Grant Hughes1, Mathilde Pioro1, Jeffrey Sparks10, Jeffrey Jarvik2, Siddharth Singh9 and Namrata Singh11, 1University of Washington, Seattle, WA, 2Department of Radiology and University of Washington Clinical Learning, Evidence, and Research (CLEAR) Center for Musculoskeletal Disorders, Seattle, WA, 3VA Puget Sound/University of Washington, Seattle, WA, 4Boston University, Boston, MA, 5Department of Rheumatology, Boston University School of Medicine, Milton, MA, 6University of Chicago Medical Center, Chicago, IL, 7Austin Health, Heidelberg, Australia, 8St. Eloi Hospital, Department of Internal Medicine and Multi-Organic Diseases, Montpellier, France, 9University of California San Diego, San Diego, CA, 10Division of Rheumatology, Inflammation, and Immunity, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, 11University of Washington, Bellevue, WA

    Background/Purpose: Concern has arisen over the safety of Janus kinase inhibitors (JAKi) regarding cardiovascular (CV) outcomes in patients with rheumatoid arthritis (RA) with CV risk…
  • Abstract Number: 0510 • ACR Convergence 2023

    Bimekizumab Treatment Improved Key Patient-Reported Symptoms of Axial Spondyloarthritis Including Spinal Pain, Fatigue, and Morning Stiffness: 52-Week Results from Two Phase 3 Studies

    Philip J. Mease1, Maxime Dougados2, Maureen Dubreuil3, Marina Nighat Magrey4, Helena Marzo-Ortega5, Martin Rudwaleit6, Christine de la Loge7, Carmen Fleurinck8, Ute Massow9, Vanessa Taieb10 and Atul Deodhar11, 1Swedish Medical Center/Providence St. Joseph Health and University of Washington School of Medicine, Seattle, WA, 2Department of Rheumatology, Hôpital Cochin, University of Paris Cité, Paris, France, 3Department of Rheumatology, Boston University School of Medicine, Milton, MA, 4Case Western Reserve University, University Hospitals, Cleveland, OH, 5NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust and Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, 6University of Bielefeld, Klinikum Bielefeld, Bielefeld, Germany, 7UCB Pharma, Brussels, Belgium, 8UCB Pharma, Oosterzele, Belgium, 9UCB Pharma, Monheim am Rhein, Germany, 10UCB Pharma, Colombes, France, 11Division of Arthritis and Rheumatic Disease, Oregon Health & Science University, Portland, OR

    Background/Purpose: Bimekizumab (BKZ) is a monoclonal IgG1 antibody that selectively inhibits IL-17F in addition to IL-17A. In the phase 3 studies BE MOBILE 1 and…
  • Abstract Number: 0521 • ACR Convergence 2023

    Work Productivity Improved in Patients with Axial Spondyloarthritis Receiving Bimekizumab Treatment over 52 Weeks: Results from Two Phase 3 Studies

    Martin Rudwaleit1, Victoria Navarro-Compán2, Atul Deodhar3, Maureen Dubreuil4, Michael Frank Mørup5, Vanessa Taieb6, Christine de la Loge7, Carmen Fleurinck8, Ute Massow9, Thomas Vaux10 and Annelies Boonen11, 1University of Bielefeld, Klinikum Bielefeld, Bielefeld, Germany, 2Department of Rheumatology, La Paz University Hospital, IdiPaz, Madrid, Spain, 3Division of Arthritis and Rheumatic Disease, Oregon Health & Science University, Portland, OR, 4Department of Rheumatology, Boston University School of Medicine, Milton, MA, 5UCB Pharma, Copenhagen, Denmark, 6UCB Pharma, Colombes, France, 7UCB Pharma, Brussels, Belgium, 8UCB Pharma, Oosterzele, Belgium, 9UCB Pharma, Monheim am Rhein, Germany, 10UCB Pharma, Slough, United Kingdom, 11Care and Public Health Research Institute (Caphri), Maastricht University, Maastricht, Netherlands

    Background/Purpose: The clinical manifestations of axial spondyloarthritis (axSpA) limit physical function and work productivity, posing an economic burden to patients (pts) and society.1 Bimekizumab (BKZ),…
  • Abstract Number: 0526 • ACR Convergence 2023

    Bimekizumab Improved Physical Function and Health-Related Quality of Life in Patients with Axial Spondyloarthritis: 52-Week Results from Two Phase 3 Studies

    Maureen Dubreuil1, Karl Gaffney2, Jonathan Kay3, Victoria Navarro-Compán4, Christine de la Loge5, Alicia Ellis6, Carmen Fleurinck7, Ute Massow8, Vanessa Taieb9 and Atul Deodhar10, 1Department of Rheumatology, Boston University School of Medicine, Milton, MA, 2Norfolk and Norwich University Hospital NHS Trust, Norfolk, United Kingdom, 3Division of Rheumatology, Department of Medicine, UMass Chan Medical School and UMass Memorial Medical Center, Worcester, MA, 4Department of Rheumatology, La Paz University Hospital, IdiPaz, Madrid, Spain, 5UCB Pharma, Brussels, Belgium, 6UCB Pharma, Raleigh, NC, 7UCB Pharma, Oosterzele, Belgium, 8UCB Pharma, Monheim am Rhein, Germany, 9UCB Pharma, Colombes, France, 10Division of Arthritis and Rheumatic Disease, Oregon Health & Science University, Portland, OR

    Background/Purpose: Axial spondyloarthritis (axSpA) severely impairs physical function and health-related quality of life (HRQoL).1 Bimekizumab (BKZ), a monoclonal IgG1 antibody that selectively inhibits IL-17F in…
  • Abstract Number: 0739 • ACR Convergence 2023

    Major Adverse Cardiovascular Event and Venous Thromboembolism Risk Comparing Advanced Therapies Among Individuals with Axial Spondylarthritis and Psoriatic Arthritis

    Sali Merjanah1, Devin Driscoll2, Christine Peloquin3, Jean liew3 and Maureen Dubreuil4, 1Boston University Chobanian & Avedisian School of Medicine, Boston, MA, 2Boston University/Boston Medical Center, Boston, MA, 3Boston University, Boston, MA, 4Department of Rheumatology, Boston University School of Medicine, Milton, MA

    Background/Purpose: Individuals with axial spondyloarthritis (axSpA) and psoriatic arthritis (PsA) have increased cardiovascular risk compared to the general population, which is partly explained by systemic…
  • Abstract Number: 0841 • ACR Convergence 2023

    Spondyloarthritis Research and Treatment Network (SPARTAN) Draft Referral Recommendations for Axial Spondyloarthritis

    Maureen Dubreuil1, Abhijeet Danve2, Swetha Ann Alexander3, Mohamad Bittar4, Liana Fraenkel5, Alyssa Grimshaw6, Anand Kumthekar7, Michael LaValley8, Jean liew9, Marina Nighat Magrey10, Vikas Majithia11, Sali Merjanah12, Hillary Norton13, Jessica A Walsh14 and Atul Deodhar15, 1Department of Rheumatology, Boston University School of Medicine, Milton, MA, 2Yale University School of Medicine, Glastonbury, CT, 3University of Utah Health, Salt Lake City, UT, 4The University of Tennessee Health Science Center, Memphis, TN, 5Berkshire Health Systems, Lenox, MA, 6Yale University, New Haven, CT, 7Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, NY, 8Boston University School of Public Health, Arlington, MA, 9Boston University, Boston, MA, 10Case Western Reserve University, University Hospitals, Cleveland, OH, 11Mayo Clinic Florida, Jacksonville, FL, 12Boston University Chobanian & Avedisian School of Medicine, Boston, MA, 13Inspire Santa Fe Rheumatology, Santa Fe, NM, 14Salt Lake City Veterans Affairs Health and University of Utah Health, Division of Rheumatology, Salt Lake City, UT, 15Division of Arthritis and Rheumatic Disease, Oregon Health & Science University, Portland, OR

    Background/Purpose: In the United States (US), the diagnosis of axial spondyloarthritis (axSpA) continues to be delayed by an average of 10 years from symptom onset.…
  • Abstract Number: 1386 • ACR Convergence 2023

    Opioid Prescription Rates in Patients with Ankylosing Spondylitis in the UK Between 2001-2020: An Electronic Health Records (EHR) Analysis

    Huseyin Berk Degirmenci1, Christine E. Peloquin2, Sara Lodi2, Pedro Machado3, S. Reza Jafarzadeh4, Tuhina Neogi5, Lianne Gensler6, Maureen Dubreuil7 and Jean Liew2, 1St. Elizabeth's Medical Center, Boston, MA, 2Boston University, Boston, MA, 3Centre for Rheumatology & Department of Neuromuscular Diseases, University College London, London, UK. Department of Rheumatology, Northwick Park Hospital, London North West University Healthcare NHS trust, London, UK., London, United Kingdom, 4Boston University Chobanian & Avedisian School of Medicine, Boston, MA, 5Boston University School of Medicine, Boston, MA, 6University of California San Francisco, Department of Medicine, Division of Rheumatology, San Francisco, CA, 7Department of Rheumatology, Boston University School of Medicine, Milton, MA

    Background/Purpose: Although current axial spondyloarthritis (axSpA) management guidelines do not address opioid use for chronic pain, available data show that opioid use is common among…
  • 1
  • 2
  • 3
  • 4
  • Next Page »
Search Again »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology